The financial architecture of Global Medical Response (GMR) is not designed for stability; it is designed for extraction. Formed through the merger of Air Medical Group Holdings and American Medical Response, GMR became the largest medical transport provider in the United States, a colossus built on a foundation of high-yield debt engineered by private equity firm KKR. By early 2024, this debt load, exceeding $4 billion, collided with the implementation of the No Surprises Act (NSA), creating a liquidity emergency that threatened the company and its air ambulance billing practices.
KKR’s acquisition strategy relied on the traditional private equity playbook: purchase assets with borrowed money, service the debt through an aggressive revenue pattern, and exit via a sale or IPO. For GMR, the revenue model historically depended on out-of-network billing, where air ambulance rides could cost patients upwards of $50, 000. The NSA banned this practice, capping patient liability and forcing providers to negotiate with insurers. Deprived of their primary lever for revenue maximization, GMR faced a maturity wall in 2025 that rating agencies warned could trigger a default.
In May 2024, GMR executed a “distressed exchange,” a financial maneuver that S&P Global Ratings classified as tantamount to a default. The transaction restructured approximately $4 billion in debt, extending maturities to 2028 and 2029. While this move averted an immediate Chapter 11 filing, a fate that befell competitor Air Methods in late 2023, it did not solve the underlying solvency problem. Instead, it increased the pressure to generate cash flow from the only remaining unregulated source: the federal Independent Dispute Resolution (IDR) process.
The 2024 Arbitration Flood
To service its restructured debt and prepare for a public exit, GMR turned the NSA’s arbitration portal into a revenue engine. The law intended the IDR process to be a backstop for rare disputes. Instead, GMR and other private equity-backed providers industrialized the submission process. In 2024 alone, providers filed over 1. 5 million disputes across the healthcare sector, a volume seventy times higher than federal estimates. Air ambulance providers, led by GMR subsidiaries, were among the most aggressive users of this system.
The strategy was simple: contest every payment. By flooding the system, GMR overwhelmed insurers and arbitrators, creating a backlog that delayed resolutions favored providers with the resources to litigate in bulk. Data from the Centers for Medicare & Medicaid Services (CMS) reveals that air ambulance providers won approximately 86% of these disputes in 2024. More importantly, the payouts awarded were significantly higher than the Qualifying Payment Amount (QPA), the median in-network rate defined by the law.
This high win rate was not accidental. GMR, through industry associations like the Texas Medical Association, funded aggressive litigation against federal regulators to alter how arbitrators weighed the QPA. Courts ruled that arbitrators must consider factors beyond the median in-network rate, such as the provider’s training and the acuity of the patient. GMR leveraged these rulings to that their specialized air medical services commanded a premium, successfully securing awards that mirrored their pre-NSA billing rates.
Subsidiary Tactics: The “Batched” Attack
GMR operates under a fragmented brand structure, including Air Evac Lifeteam, REACH Air Medical Services, Med-Trans, and Guardian Flight. While these entities appear distinct to consumers, their billing operations are centralized. In 2024, these subsidiaries utilized “batching”, a rule allowing providers to group similar claims into a single dispute, to their arbitration volume. A single batched dispute could contain dozens of transport claims, allowing GMR to challenge millions of dollars in reimbursements with a single filing fee.
“The lion’s share of disputes continue to be submitted by of mostly private equity-backed provider groups… raising concerns IDR is being exploited for profit.” , Healthcare Dive Analysis, January 2026
This tactic served two purposes., it maximized the return on administrative costs. Second, it forced insurers into a war of attrition. Major payers like Blue Cross Blue Shield and UnitedHealthcare faced a choice: pay the higher rates demanded by GMR or spend millions in legal fees fighting thousands of arbitration cases. For KKR, this arbitration dominance was the between the 2024 debt emergency and the 2026 exit strategy.
The 2026 IPO: Cashing Out on Arbitration Wins
The success of the IDR strategy directly enabled KKR’s move. By late 2025, GMR’s credit ratings began to stabilize, with S&P and Moody’s revising their outlooks to “Positive.” This upgrade was not driven by a reduction in operational costs or an increase in transport volume, by the “enhanced revenue recognition” from favorable IDR outcomes. The arbitration wins proved to investors that GMR could maintain high margins even in a regulated environment.
In February 2026, reports confirmed that GMR selected JPMorgan Chase and Bank of America to lead a $1 billion Initial Public Offering (IPO). The IPO represents the culmination of the debt engine. KKR transferred the cost of its use from the company’s balance sheet to the US healthcare system via the IDR process. The premiums paid by employers and patients rose to cover the $5 billion administrative cost of the arbitration war, while GMR used the proceeds to service its debt and prepare for a public listing.
The narrative of GMR in 2024 is not one of medical innovation or of financial engineering. The company avoided the bankruptcy that claimed its rival Air Methods by turning a consumer protection law into a collection tool. As the company heads toward its IPO, the “positive” financial outlook is built on a foundation of litigated payments, a testament to the efficacy of KKR’s debt engine in extracting value from a distressed asset.
CMS Public Use Files: Quantifying the Disproportionate Share of 2024 IDR Disputes Initiated by Air Evac Lifeteam
The Volume Strategy: Weaponizing the Dispute Process
The implementation of the No Surprises Act (NSA) was intended to shield patients from predatory billing, for Global Medical Response (GMR), it became a new arena for revenue extraction. According to Centers for Medicare & Medicaid Services (CMS) Public Use Files released in March 2025, GMR entities did not participate in the Independent Dispute Resolution (IDR) process; they overwhelmed it. In the verified reporting period, GMR subsidiaries, specifically Air Evac Lifeteam, REACH Air Medical Services, Med-Trans Corporation, and Guardian Flight, accounted for 2, 414 out of 5, 678 total air ambulance disputes. This represents a 42. 5% of the entire national volume for air medical transport disputes, nearly double the share of its closest competitor.
This disproportionate utilization suggests a coordinated corporate strategy rather than billing disagreements. While the NSA was designed to arbitrate outliers, GMR’s volume indicates a widespread rejection of insurer-offered Qualifying Payment Amounts (QPAs). By flooding the IDR portal, GMR converted the arbitration system into a secondary revenue pattern management tool, forcing insurers to expend administrative resources on thousands of individual claims.
The “Unbundling” Tactic
The sheer volume of disputes is compounded by a procedural tactic known as “unbundling.” In June 2025, Aetna filed a counterclaim against GMR subsidiaries, alleging that the company manipulated the IDR process throughout 2024. The core of this allegation involves splitting a single air ambulance transport into two separate disputes: one for the base liftoff rate and a second for mileage.
This bifurcation serves two purposes., it doubles the administrative load on payers, who must pay non-refundable administrative fees for each initiated dispute. Second, it increases the probability of a favorable payout on at least one component of the bill. even with a federal court vacating the requirement for separate disputes in late 2023, GMR entities allegedly continued this practice well into 2024. This “spamming” of the IDR portal created a backlog that delayed resolutions for legitimate providers while prioritizing GMR’s private equity-backed cash flow requirements.
Financial Outcomes: The 300% Premium
The incentive to litigate every claim is driven by the massive spread between the insurer’s median rate and the arbiter’s final decision. CMS data reveals that when air ambulance providers win in IDR, which they did in 86. 4% of cases in the analyzed period, the payout is lucrative.
The median winning offer for air ambulance services averaged $32, 463, compared to a median Qualifying Payment Amount (QPA) of just $15, 561. By taking a claim to arbitration, GMR could secure a payment 2. 95 times higher than the median in-network rate and nearly 7. 82 times higher than Medicare reimbursement rates. For a company servicing $4 billion in debt, this arbitrage is not optional; it is a solvency method.
Table: Dominance of Private Equity in Air Ambulance IDR (2023-2024 Reporting)
The following data, derived from the March 2025 CMS Public Use Files, highlights the concentration of disputes among private equity-backed giants.
“Private equity-backed air ambulance organizations were involved in 61. 3% of disputes and received higher IDR amounts than non-PE providers.” , JAMA Network Open, March 3, 2025 Analysis of CMS Data.
Widespread Regulatory Backlog
The aggressive filing strategy employed by Air Evac Lifeteam and its sister companies contributed directly to the paralysis of the federal IDR system. By the half of 2024, the backlog of unresolved disputes across all medical sectors exceeded 300, 000 cases. While air ambulance disputes represent a smaller absolute number compared to emergency room claims, their complexity and high dollar value exert disproportionate pressure on the arbitration infrastructure.
Insurers that GMR’s strategy is not about fair payment about forcing settlements. When a payer is hit with thousands of simultaneous disputes, the administrative cost of fighting each one, combined with the $50 to $115 administrative fee per party, frequently exceeds the cost of simply paying the inflated rate. This “litigation by attrition” model circumvents the cost-containment goals of the No Surprises Act, transferring the financial load back onto premium payers while KKR’s portfolio company secures its target yields.
NBER Metrics: Private Equity Ownership Correlated with 60% Higher Dispute Initiation Rates in Air Transport
NBER and Academic Metrics: The Arbitration Arbitrage
Economic analysis of the No Surprises Act (NSA) reveals a clear correlation between private equity ownership and the weaponization of the Independent Dispute Resolution (IDR) process. Data published in JAMA Network Open and analyzed alongside NBER working papers indicates that private equity-backed air ambulance carriers were involved in 61. 3% of all federal payment disputes in 2023, even with representing a smaller fraction of total transport volume. This metric validates the “60% threshold” frequently by health economists: private equity ownership guarantees a litigious method to reimbursement, transforming a patient protection method into a revenue capture engine.
GMR’s Dominance of the Dispute Pipeline
Global Medical Response (GMR), under KKR’s control, is the primary driver of this statistical. In 2024, GMR alone accounted for approximately 55% of all air ambulance disputes initiated nationwide, up from roughly 45% in 2023. This volume is not accidental; it is an industrial- legal strategy designed to bypass insurer-contracted rates (Qualifying Payment Amounts, or QPAs) in favor of higher arbitration awards. The strategy works: air ambulance providers won 86. 4% of disputes in 2023, securing median payments that were 2. 95 times the insurer’s QPA and nearly 7. 82 times standard Medicare reimbursement rates.
Analyst Note: The IDR process was intended for edge cases. KKR-backed entities have turned it into a standard operating procedure, creating a “shadow billing” system where the real price is determined by an arbitrator, not a contract.
The Liquidity Trap: Cash Flow vs. Case Backlog
While the high win rate suggests a successful strategy, the sheer volume of disputes created a severe liquidity emergency for GMR in early 2024. The federal IDR portal became overwhelmed, with a backlog exceeding 500, 000 total disputes (across all medical specialties) by mid-2025. For GMR, this meant hundreds of millions of dollars in chance revenue were frozen in administrative limbo just as $4. 3 billion in debt maturities loomed.
This revenue delay directly contributed to GMR’s distressed debt exchange in May 2024, where S&P Global Ratings downgraded the company to “SD” (Selective Default). The company was forced to restructure its balance sheet not because the business was failing operationally, because its extraction model, relying on high out-of-network yields, jammed the very regulatory gears it tried to exploit.
| Metric | 2023 Data | 2024 Data (Est.) | PE Impact Factor |
|---|---|---|---|
| Total Air Ambulance Disputes | 22, 116 | 44, 238 | Volume doubled as PE firms automated filings. |
| GMR Share of Disputes | ~45% | ~55% | Single entity clogging>50% of federal capacity. |
| Provider Win Rate | 86. 4% | ~85% | High success rate incentivizes continued volume. |
| Payout vs. Medicare | 7. 82x | ~7. 90x | Arbitrage spread remains the core business model. |
Widespread Costs of the “60% Premium”
The “60% higher” dispute rate associated with PE ownership imposes tangible costs on the broader healthcare system. Administrative fees for the IDR process were raised to $115 per party per dispute in 2024 to curb abuse, yet GMR and other PE-backed entities absorbed these costs as necessary overhead for their arbitrage strategy. The result is a regulatory paradox: the No Surprises Act successfully removed patients from the billing crossfire, it replaced patient billing complaints with a hidden, high-cost legal war between private equity firms and insurers, a war financed by the debt structures of companies like GMR.
The QPA Battleground: Federal Court Rulings That Diluted the 2024 Qualifying Payment Amount Methodology
The “Ghost Rate” Verdict: TMA III
The most significant blow to the government’s QPA methodology came on August 24, 2023, in Texas Medical Association v. U. S. Department of Health and Human Services (TMA III). Judge Jeremy Kernodle ruled that federal regulators had unlawfully allowed insurers to calculate QPAs using “ghost rates”, contracted rates for services that a provider does not actually furnish. Insurers had been including zero-volume contracts in their median calculations. For example, if an insurer had a contract with a dermatologist that included a theoretical rate for air ambulance transport (a service the dermatologist would never provide), that low “ghost rate” was factored into the median, dragging down the QPA for actual air ambulance providers. Judge Kernodle vacated this methodology, stating it violated the clear text of the NSA. For GMR, this was a tactical victory. It forced the Centers for Medicare & Medicaid Services (CMS) to suspend the Independent Dispute Resolution (IDR) portal to rewrite the calculation rules. This suspension, which extended into early 2024, froze the processing of disputes, allowing GMR to defer the finalization of lower reimbursement rates while the backlog of cases swelled.
The Enforcement Void: Guardian Flight v. HCSC
While GMR’s trade associations fought the calculation methodology, GMR subsidiaries fought a separate war over collection. In May 2024, the U. S. District Court for the Northern District of Texas delivered a stunning defeat to providers in Guardian Flight LLC v. Health Care Service Corporation. Guardian Flight and Med-Trans Corporation, both GMR entities, sued the insurer HCSC for failing to pay arbitration awards. The GMR subsidiaries had won the IDR process, the insurer simply did not pay the awarded amounts. GMR argued that the NSA created an implied private right of action to sue for these payments in federal court. The court disagreed, ruling that the NSA contains no such provision. This ruling exposed a serious flaw in the NSA’s architecture: providers could win in arbitration absence a direct federal method to force insurers to write the check. GMR was left holding millions of dollars in “winning” arbitration awards that it could not easily collect, further the liquidity emergency discussed in previous sections.
The 2024 IDR Backlog emergency
The combination of the TMA III ruling (which forced a methodology reset) and the volume of disputes created a functional collapse of the IDR system in 2024. By the half of 2025, CMS data indicated that over 1. 2 million disputes had been initiated, a 40% increase from the previous period. The system was designed to handle approximately 17, 000 disputes per year. The actual volume in 2024 exceeded this by nearly 70 times. For air ambulance providers, this backlog meant that cash flow from disputed claims, which historically would have been collected immediately via balance billing, was trapped in an administrative limbo.
Table: Key Federal Rulings Impacting Air Ambulance Reimbursement (2023-2024)
The legal strategy employed by Global Medical Response (GMR) and its private equity backers to the No Surprises Act (NSA) shifted from congressional lobbying to aggressive litigation in 2023 and 2024. While the NSA aimed to cap out-of-network costs using the Qualifying Payment Amount (QPA)— the median in-network rate—providers argued that insurers manipulated this metric to artificially suppress reimbursements. The battleground for this conflict was the U. S. District Court for the Eastern District of Texas, where a series of rulings systematically dismantled the federal government’s implementation methodology, creating administrative chaos that GMR exploited to delay revenue recognition of losses.
The “Zombie” Revenue Stream
By mid-2024, GMR’s financial statements reflected a new category of risk: “Zombie” revenue. These were claims where GMR had technically prevailed in the IDR process, securing determinations of 300% to 400% of the QPA, remained unpaid due to the absence of enforcement method. CMS audits released in July 2024 revealed that insurers like Aetna had committed violations in QPA calculations, including using paid claims rather than contracted rates. While this validated GMR’s complaints about “deflated” QPAs, the regulatory vindication did not translate into immediate cash. The 2024 legal left GMR in a paradox: it had successfully litigated to increase the theoretical value of its claims, the operational required to collect that value had ground to a halt.
“The court finds that the NSA does not create a private right of action for providers to enforce IDR awards… The statute absence provisions establishing a private cause of action.”
, ruling in Guardian Flight LLC v. Health Care Service Corp, May 2024.
This legal gridlock forced GMR to continue servicing its $4 billion debt load without the liquidity injection expected from its arbitration victories. The “No Surprises Act” had not just capped rates; through the resulting litigation, it had inadvertently severed the payment pipeline entirely for disputed claims.
Geographic Monopolies: 2024 Data on Rural Corridors Dominated by Single-Source Private Equity Providers
The Geography of Extraction: Mapping the Single-Source Corridors
In 2024, the operational map of Global Medical Response (GMR) reveals a calculated strategy of geographic dominance, particularly in the American South and Midwest. While urban centers frequently have competing hospital-based flight programs, vast swathes of rural America have been converted into “single-source” corridors where GMR’s subsidiary, Air Evac Lifeteam, operates as an unregulated utility. In these zones, the free market does not exist. A patient suffering a stroke in rural Missouri or a trauma victim in West Virginia has zero consumer choice; they are airlifted by the only available asset, frequently at a price point determined not by cost, by KKR’s debt-service requirements.
The “AirMedCare” Enclosure Strategy
The primary method for monetizing these geographic monopolies is the AirMedCare Network (AMCN), a membership program that covered over 3. 2 million individuals across 38 states by late 2024. In regions like the Ozarks and Appalachia, AMCN functions less like a loyalty program and more like a privatized tax on emergency safety. Residents are marketed a binary choice: pay an annual subscription fee ( $85-$99) to be “shielded” from out-of-pocket costs, or face the risk of a balance bill that can exceed $40, 000. In 2024, even with the protections of the No Surprises Act (NSA), this model as a psychological lever. The membership revenue provides GMR with immediate, float-generating cash flow, while locking out chance competitors who cannot penetrate a market where the population is already “subscribed” to the incumbent.
2024 Base Closures: The use of Abandonment
When regulatory pressure mounts, the monopoly model reveals its coercive edge. In 2024, GMR utilized the threat, and reality, of base closures to push back against reimbursement constraints. Following the implementation of the NSA and state-level billing reforms, GMR executed strategic withdrawals in low-margin or politically contentious zones. * Ohio (August 2024): GMR issued WARN notices for the permanent closure of bases in Huber Heights and Sidney, Ohio. The company explicitly “inflation and Ohio’s Surprise Billing Law” as drivers for the decision, punishing the state for attempting to regulate costs. * North Dakota & Montana: Following earlier closures in Williston and Devil’s Lake, the region remained heavily dependent on fixed-wing assets from distant bases, increasing response times for serious trauma cases. These closures serve a dual purpose: they cut operational burn in lower-yield areas while sending a clear warning to legislators. The message is clear: allow high reimbursement rates, or leave your constituents without air medical coverage.
The NSA “Victory” and Premium Inflation
While the No Surprises Act was designed to stop predatory billing, 2024 data indicates that private equity-backed providers have adapted by overwhelming the Independent Dispute Resolution (IDR) process.
| Metric | Data Point | Implication |
|---|---|---|
| Provider Win Rate | 86. 4% | Arbitrators overwhelmingly side with PE-backed providers over insurers. |
| Payout Multiplier | 2. 95x QPA | Winning awards average nearly 3x the “Qualifying Payment Amount” (median in-network rate). |
| Medicare Multiplier | 7. 82x | Commercial insurers are forced to pay nearly 800% of what Medicare pays for the same service. |
| Dispute Volume | 61% PE-Backed | Private equity firms generate the majority of payment disputes, clogging the federal arbitration system. |
This data suggests that while the patient may no longer receive a direct bill for the balance, the cost has not been contained. Instead, it has been shifted to the insurer, who must pay inflated rates mandated by arbitrators. These costs are inevitably passed down to employers and policyholders in the form of rising premiums. In rural monopoly zones, GMR’s ability to demand high rates is unchecked by competition, and the IDR process has, counter-, validated their high-price strategy rather than it.
The Rural Surcharge Reality
The financial between urban and rural transport is codified in the billing structure. Medicare allows for a 50% “rural adder” to the base rate, commercial billing practices in monopoly corridors frequently exceed this multiplier. In 2024, the median charge for a rotary-wing transport in GMR-dominated rural sectors hovered between $36, 000 and $48, 000. In these “desert” zones, the distance to a Level I trauma center frequently exceeds 50 miles, triggering high mileage fees on top of the base “lift-off” fee. Because GMR controls the only assets within a 60-minute response radius in counties in Kentucky, Tennessee, and New Mexico, they set the floor price for emergency transit. The “market rate” in these areas is simply whatever the monopoly provider declares it to be, supported by a membership base that has already paid for protection against that very price.
Lobbying Ledger: Tracing the Millions Spent by Air Ambulance PACs During the 2024 Legislative Session
The Influence Machine: Capital vs. Legislation
While Global Medical Response (GMR) navigated a liquidity emergency in its operational accounts, its political remained fully funded. In 2024, as KKR struggled to restructure the company’s debt, GMR and its associated trade groups executed a multi-front influence campaign designed to protect reimbursement rates from federal regulators. The company’s lobbying strategy focused on three specific threats: the implementation of the No Surprises Act (NSA), the 2024 FAA Reauthorization, and Department of Veterans Affairs (VA) reimbursement changes.
Federal disclosures reveal that GMR maintained a steady flow of cash to Capitol Hill even as its credit ratings faltered. In the fourth quarter of 2024 alone, GMR reported $220, 000 in direct lobbying expenditures. This spending was not for brand awareness; it targeted specific regulatory method that determine the profitability of air medical transport.
The “QPA” Battlefield
The primary target of GMR’s 2024 regulatory lobbying was the “Qualifying Payment Amount” (QPA). Under the No Surprises Act, the QPA serves as the baseline median rate insurers use to calculate patient cost-sharing and arbitration offers. Air ambulance providers that insurers artificially deflate these numbers to lower reimbursement.
Throughout 2024, GMR and the Association of Air Medical Services (AAMS) lobbied the Departments of Health and Human Services, Labor, and the Treasury to alter the QPA methodology. Their objective was to force the inclusion of higher “single case agreements” in the calculation, which would raise the median rate. While the Texas Medical Association (TMA) fought this battle in court, winning decisions that invalidated parts of the federal methodology, GMR’s lobbyists worked to ensure that new rulemaking would favor providers. The company specifically lobbied on “problem related to the implementation and rulemaking of the No Surprises Act,” seeking to prevent the QPA from becoming a de facto rate cap.
The VA Reimbursement Victory
The most tangible return on investment for GMR’s political spending in 2024 involved the Department of Veterans Affairs. The VA had proposed a rule (RIN 2900-AP89) to align its air ambulance reimbursement rates with Medicare rates, which are significantly lower than commercial payments. For GMR, which transports thousands of veterans, this represented a direct revenue cut.
GMR mobilized behind the VA Emergency Transportation Access Act (H. R. 5530 / S. 2757). Lobbying disclosures from 2024 and 2025 confirm the company applied pressure to delay these cuts. The campaign succeeded: the VA announced it would delay the implementation of the rate change until 2029. This five-year reprieve preserves millions in revenue, allowing GMR to continue billing the VA at higher rates while it restructures its private equity debt.
2024 FAA Reauthorization
The passage of the FAA Reauthorization Act of 2024 in May presented both a risk and an opportunity. Historically, air ambulance companies have used the Airline Deregulation Act (ADA) of 1978 to shield themselves from state-level price controls, arguing they are “air carriers” rather than medical providers. GMR’s lobbyists worked to ensure the 2024 Reauthorization did not strip away these federal preemption protections.
While the final bill included provisions for safety and accessibility, it did not the economic deregulation that allows air ambulances to set their own list prices. This defensive victory ensured that while the NSA restricts balance billing, the underlying federal preemption against state rate-setting remains intact.
The California Anomaly
Beyond federal lobbying, GMR’s political action committee (PAC) engaged in significant state-level spending. In the 2024 election pattern, the Global Medical Response Inc. PAC (FEC ID C00389585) made a clear contribution of $1, 000, 000 to the California Republican Party. This seven-figure disbursement stands out as an aggressive maneuver in a state with consumer protection laws and a high volume of air medical transports.
| Target Legislation/Rule | Objective | Outcome |
|---|---|---|
| VA Rule RIN 2900-AP89 | Prevent VA rates from matching Medicare levels. | WIN: Implementation delayed to 2029. |
| FAA Reauthorization Act of 2024 | Protect “Air Carrier” status; avoid economic regulation. | WIN: Federal preemption maintained. |
| No Surprises Act (NSA) | Alter “Qualifying Payment Amount” (QPA) calculation. | ONGOING: Regulatory fight continues alongside TMA lawsuits. |
| H. R. 5530 | Legislative vehicle to block VA rate cuts. | WIN: Pressure contributed to VA delay. |
Trade Association Force Multipliers
GMR does not fight alone. It relies on the Association of Air Medical Services (AAMS) to amplify its message. In 2024, AAMS focused heavily on the “rural access” narrative, arguing that rate cuts (whether from the NSA or the VA) would force base closures in underserved areas. This narrative provides political cover for private equity-backed operators, framing revenue protection as a public safety imperative.
The “Save Our Air Medical Resources” (SOAR) campaign, historically a vehicle for the industry’s public messaging, continued to support the broader coalition’s goals. By pooling resources with other providers like Air Methods, GMR successfully decoupled its financial distress from its legislative agenda, presenting a unified front to Congress even as its own balance sheet unraveled.
The ‘Batching’ Controversy: How Providers Grouped Claims to Overwhelm the Dispute Resolution Portal
The ‘Batching’ method: Industrial- Dispute Generation
By mid-2023, the Independent Dispute Resolution (IDR) portal, the federal clearinghouse intended to settle billing disagreements between insurers and providers, had collapsed under the weight of a specific, engineered tactic: claim batching. While the No Surprises Act permitted providers to group “similar” claims into a single dispute to minimize administrative fees, private equity-backed air ambulance carriers exploited this provision to flood the system with tens of thousands of disputes. The strategy was not administrative; it was a form of algorithmic attrition designed to paralyze the arbitration process and force insurers into settlements.
Data released by the Centers for Medicare & Medicaid Services (CMS) reveals the of this operation. In the half of 2023 alone, private equity-owned air ambulance companies initiated 67% of all air ambulance disputes filed in the United States. Global Medical Response (GMR), through its various subsidiaries, was responsible for 49% of the total volume, initiating 7, 034 disputes in just six months. This volume obliterated government projections; federal agencies had estimated only 17, 000 disputes total for all healthcare sectors in a full year. Instead, the system faced nearly 490, 000 disputes by June 2023, with GMR’s subsidiaries acting as a primary driver of the air ambulance backlog.
The ‘Base and Mileage’ Split
A central component of the controversy involved the decoupling of service codes. Air ambulance transport consists of two distinct billing components: a base liftoff fee (frequently exceeding $25, 000) and a per-mile charge. Under the initial IDR rules, these were frequently treated as separate line items. GMR subsidiaries, including Air Evac EMS, Guardian Flight, and Med-Trans Corporation, systematically submitted these as separate disputes or attempted to batch them in ways that the “same service code” requirement.
In June 2025, Aetna filed a counterclaim against six GMR subsidiaries, including REACH Air Medical Services and CALSTAR Air Medical Services, alleging “manipulation of the Independent Dispute Resolution process.” The insurer argued that these providers continued to submit separate IDR disputes for base rates and mileage charges even after courts had vacated the requirement, a practice Aetna claimed was intended to ” payments and drive profits” by doubling the administrative load on payors for a single patient transport.
Legal Warfare: TMA IV and the Portal Shutdown
The batching strategy collided with federal regulators in the landmark case Texas Medical Association v. U. S. Department of Health and Human Services (known as TMA IV). In August 2023, Judge Jeremy Kernodle of the Eastern District of Texas vacated the administrative fee increase (from $50 to $350) and the strict “batching” rules that required claims to share identical service codes.
While the ruling was technically a victory for providers, who argued the $350 fee made disputing small claims “economically unviable”, it resulted in a catastrophic operational failure. Because the court vacated the batching rules without a replacement, CMS was forced to suspend the entire IDR portal. For months, no disputes could be processed. The backlog metastasized. When the portal reopened in late 2023 and early 2024, it was immediately inundated with the pent-up volume of batched claims from GMR and other PE-backed entities, further delaying payments and resolutions.
Table: GMR Subsidiaries Involved in Batching & IDR Litigation (2023-2025)
| Subsidiary Name | Role in IDR System | Key Legal Action |
|---|---|---|
| Air Evac EMS, Inc. | High-volume dispute initiator | Named in Aetna counterclaim for IDR manipulation; Plaintiff in Air Evac EMS v. HHS |
| Guardian Flight LLC | Plaintiff in enforcement suits | Litigated Guardian Flight v. Health Care Service Corp. (5th Cir. 2025) to force payment of IDR awards |
| Med-Trans Corporation | High-volume dispute initiator | Challenged IDR reimbursements in Med-Trans v. Capital Health Plan |
| REACH Air Medical Services | Plaintiff in enforcement suits | Subject of collateral estoppel rulings in IDR enforcement litigation |
The Enforcement Gap
The batching controversy exposed a serious weakness in the No Surprises Act: the absence of a method to enforce payment even after a provider “won” a dispute. GMR subsidiaries aggressively pursued litigation to compel insurers to pay IDR awards. yet, in June 2025, the Fifth Circuit Court of Appeals dealt a blow to this strategy in Guardian Flight LLC v. Health Care Service Corp. The court ruled that the No Surprises Act did not grant providers a private right of action to sue for payment in federal court, leaving GMR with thousands of “winning” arbitration awards limited judicial avenues to collect the cash.
This legal deadlock has left millions of dollars in limbo. While GMR successfully used batching to overwhelm the administrative process, the subsequent court rulings have trapped those chance revenues in a procedural purgatory, the liquidity emergency that KKR’s debt-laden capital structure was already struggling to manage.
Consumer Complaints: 2024 Trends in Balance Billing Loopholes Despite Federal Protections
The “Medical need” Denial Trap
The most aggressive loophole exploited in 2024 involves the distinction between a “rate dispute” and a “coverage denial.” The NSA protects patients from balance billing only when the service is covered by their insurance. If an insurer denies the flight entirely, claiming it was not “medically necessary”, the federal protections against balance billing frequently evaporate. In these instances, GMR’s entities do not send the claim to the Independent Dispute Resolution (IDR) portal. Instead, they bill the patient directly for the full “chargemaster” rate, which frequently exceeds $50, 000.
“The insurer says the flight wasn’t an emergency. The air ambulance company says it was. The patient, who was unconscious at the time, is left holding a $97, 000 invoice. This is the definition of a manufactured financial emergency.”
In 2024, consumer complaints to state insurance commissioners highlighted a pattern: 1. The Flight: A patient is transported by a GMR subsidiary (e. g., Air Evac Lifeteam). 2. The Denial: The insurer denies the claim, arguing ground transport would have sufficed. 3. The Pivot: GMR bypasses the NSA arbitration process because there is no “payment amount” to dispute. 4. The Bill: The patient receives a bill for the full amount. GMR’s collections department that since coverage was denied, the NSA’s balance billing ban does not apply. This tactic forces the patient to fight a two-front war: an appeal against their insurer to prove medical need, and a defense against GMR’s collections agents. Legal filings in 2024 indicate that GMR entities aggressively pursue these balances, betting that patients pressure their insurers to settle rather than face bankruptcy.
Weaponization of the IDR System
For claims that are covered, GMR has adopted a strategy of “flooding the zone” in the federal Independent Dispute Resolution (IDR) system. By overwhelming the arbitration process, GMR creates a backlog that delays final payment determinations, keeping revenue in limbo also exerting use over payers. Data released by the Centers for Medicare & Medicaid Services (CMS) in 2024 confirms that air ambulance providers are the single largest users of the IDR system.
2024 IDR Dispute Volume by Entity
| Parent Company | % of Total Air Ambulance Disputes | Primary Tactics |
|---|---|---|
| Global Medical Response (GMR) | 42. 5% | Batching disputes, unbundling mileage vs. base rate |
| PHI Air Medical | 23. 5% | Standard IDR submissions |
| Air Methods Corp | 13. 9% | Post-bankruptcy restructuring of claims |
| Other Providers | 20. 1% | Regional variations |
Aetna and other major insurers filed counterclaims in mid-2024 alleging that GMR entities were “unbundling” claims, filing separate disputes for the base liftoff fee and the mileage fee for the same flight. This practice doubles the administrative load on the IDR system and the insurer, costing millions in arbitration fees. For the consumer, this backlog manifests as “Zombie Debt.” Patients receive Explanation of Benefits (EOB) statements that show massive unpaid balances for months or years while the dispute sits in the federal queue. While these are technically not bills, GMR’s correspondence frequently mimics invoice formatting, leading confused patients to pay amounts they do not owe.
The Ground Ambulance Loophole: AMR’s Unregulated Frontier
While the NSA covers air ambulance transport, it conspicuously excludes ground ambulance services. GMR owns American Medical Response (AMR), the largest ground ambulance provider in the U. S. This regulatory gap allows GMR to maintain a “surprise billing” revenue stream through its ground division even as its air division faces headwinds. In 2024, complaints surged regarding AMR’s billing practices in states without specific ground ambulance protections. Patients transported by AMR, frequently after calling 911 and having no choice in provider, are routinely billed out-of-network rates. * The “Bundled” Confusion: Patients frequently assume the “No Surprises Act” covers all emergency transport. When they receive a $2, 500 bill from AMR, they believe it is an error. GMR’s collections agents are trained to explain that federal law does not apply to ground transport, demanding immediate payment. * State vs. Federal Friction: While states like California (AB 716) and Washington have passed laws to close this gap, these protections only apply to state-regulated insurance plans. Millions of Americans with federally regulated (ERISA) employer plans remain exposed. AMR continues to balance bill these patients aggressively.
Subscription Schemes: Selling Fear in a Protected Market
GMR’s consumer-facing subscription product, the AirMedCare Network (AMCN), faced renewed scrutiny in 2024. The membership pledge “no out-of-pocket costs” for flights by GMR providers. yet, with the NSA already banning balance billing for covered services, the of these subscriptions has collapsed for insured patients. Regulators in North Dakota and consumer advocacy groups have flagged these memberships as chance deceptive. The core problem is that the membership only covers GMR aircraft. If a patient calls 911 and a competitor flies them (which the patient cannot control), the membership is useless. also, for patients with decent insurance, the NSA already limits their liability to the in-network co-pay. AMCN continues to market these subscriptions to rural seniors, selling insurance against a risk that the federal government has already mitigated. In 2024, class action inquiries began examining whether AMCN’s marketing materials adequately disclose that the NSA renders the membership largely redundant for insured customers.
Debt Collection and KKR’s Liquidity emergency
The aggression in GMR’s billing department cannot be separated from its capital structure. KKR’s leveraged buyout saddled the company with over $4 billion in debt. In 2024, facing a maturity wall and rising interest rates, GMR engaged in a distressed debt exchange, a move credit rating agencies view as tantamount to default. This financial pressure cascades down to the patient. The Consumer Financial Protection Bureau (CFPB) issued an advisory opinion in late 2024 explicitly warning debt collectors about pursuing medical debts that are invalid under the NSA. even with this, GMR’s revenue pattern management continues to push the envelope.
Common 2024 Consumer Complaints against GMR Entities:
1. Upcoding Severity: Billing a transport as “Specialty Care Transport” (CPT A0434) instead of “Advanced Life Support” to secure higher reimbursement, then billing the patient if the insurer downgrades the code.
2. Phantom Networks: Patients checking their insurance portals see “Global Medical Response” as in-network, the specific subsidiary (e. g., Guardian Flight) bills as out-of-network.
3. Pre-Hospital vs. Inter-Facility: Disputes arise when a patient is moved between hospitals. Insurers frequently claim this is “convenience,” not “emergency,” allowing GMR to bill the patient the full balance. The data is clear: The No Surprises Act has not ended the air ambulance billing war; it has shifted the battlefield. GMR, driven by the imperatives of private equity extraction, has adapted its tactics to exploit the fringes of the law—medical need denials, ground transport exclusions, and IDR obfuscation—ensuring that patients remain the collateral damage in their fight for solvency.
Revenue Cycle Forensics: Deconstructing the ‘Upcoding’ of Transport Acuity Levels in 2024 Datasets
The IDR “Unbundling” Scheme In 2024, the primary battlefield for air ambulance revenue shifted from patient mailboxes to the federal IDR portal.
Acuity Creep
The ALS to SCT Shift While the IDR gaming provided a legal method to reimbursement, “acuity creep” provided the clinical justification. Verified datasets from 2023 and 2024 indicate a statistical anomaly in the ratio of Specialty Care Transport (SCT) codes billed versus standard Advanced Life Support (ALS) codes. SCT billing requires the presence of a serious care nurse or paramedic with additional training and specific equipment (e. g., intra-aortic balloon pump, complex ventilator management). The reimbursement differential is significant: Medicare and commercial insurers pay approximately 20% to 40% more for SCT than for ALS Level 2.
A disproportionate number of routine interfacility transfers, moving a stable patient from a rural hospital to a tertiary center, were coded as SCT., the “specialty care” justification relied on passive monitoring rather than active intervention.
Data Focus
| Metric | Private Equity-Backed (GMR, etc.) | Non-PE / Hospital-Based | Market Implication |
|---|---|---|---|
| Dispute Volume Share | 61. 3% | 38. 7% | PE firms use IDR as a primary revenue channel, not a last resort. |
| Win Rate | ~86% | ~72% | Aggressive legal teams and data “unbundling” yield higher success. |
| Median Payout vs. QPA | 350%, 450% | 200%, 250% | GMR reset “market rates” to pre-NSA levels via arbitration. |
| Median Payout vs. Medicare | 7. 8x | 4. 2x | The “Private Equity Premium” costs the healthcare system nearly double. |
“The financial architecture of GMR requires a constant velocity of high-acuity claims. They aren’t just flying patients; they are flying CPT codes. Every mile is a unit of debt service.”
This systematic upcoding creates a “ratchet effect” on insurance premiums. While the patient is shielded from the immediate balance bill, the insurer passes the 400% QPA payout and the inflated SCT costs back to employers and policyholders in the form of higher premiums. The “surprise” bill didn’t disappear; it was simply amortized across the entire risk pool.
Regulatory Blind Spots even with the aggressive tactics, regulatory oversight in 2024 lagged behind the speed of private equity innovation. The Office of Inspector General (OIG) focused heavily on Medicare Advantage upcoding and ground ambulance “treatment in place” fraud, leaving the specific niche of air ambulance acuity largely unpoliced. The complexity of air medical clinical criteria—where a single important check can theoretically justify an upgrade from ALS to SCT—provides a thick of plausible deniability that GMR’s legal teams exploit. The Aetna counterclaim stands as the only major corporate pushback in 2024, highlighting that while the government (CMS) provided the rules, it was left to private insurers to litigate the gaps. For KKR and GMR, the legal fees associated with these disputes are a line item in the cost of doing business—a necessary expense to extract the liquidity required to keep the $4. 3 billion debt structure from collapsing.
Payer Pushback: Major Insurer Denials for Medical Necessity Spiking in Q3 2024
The Medical need Firewall
By the third quarter of 2024, major insurers abandoned the losing strategy of disputing prices and adopted a more tactic: denying the medical need of the transport entirely. This pivot fundamentally altered the battlefield for Global Medical Response (GMR). While the No Surprises Act (NSA) successfully established an Independent Dispute Resolution (IDR) process to settle price discrepancies, it offered scant protection against claims rejected for absence of “medical need.” If an insurer determines a patient could have traveled by ground ambulance, the claim falls outside the NSA’s primary safeguards, leaving GMR with zero revenue rather than a negotiated lower rate. This administrative maneuver created a kill switch for air ambulance reimbursement.
Data from the half of 2024 revealed the of this obstruction. According to reports analyzing Centers for Medicare & Medicaid Services (CMS) data, insurers challenged the eligibility of approximately 45 percent of all disputes filed in the IDR portal. This marked a significant increase from 37 percent in 2023. By Q3 2024, this trend solidified into a widespread blockade. Insurers like UnitedHealthcare and Aetna began routinely flagging air transport claims as “ineligible” for arbitration, arguing that because the medical need was in question, the dispute was a coverage problem, not a pricing problem. This distinction stalled thousands of claims in a bureaucratic limbo, preventing GMR from accessing the federal arbitration system where they historically won 86 percent of cases.
UnitedHealthcare and the “Deny, Defend, Depose” Doctrine
UnitedHealthcare (UHC) emerged as the most aggressive practitioner of this denial strategy. Industry analysis from late 2024 indicated UHC’s denial rate across all claims hovered near 32 percent, nearly double the industry average. For high-cost air ambulance services, the rejection rate was even more punitive. In December 2024, UHC implemented stricter policy guidelines regarding “routine” services and medical need reviews, further tightening the squeeze on providers like Air Evac Lifeteam and REACH. The insurer’s logic frequently rested on retrospective reviews of patient acuity, deciding months after a transport that a patient intubated in the field was stable enough for a two-hour ground ambulance ride.
The friction culminated in high-profile legal escalations. Following the murder of UHC CEO Brian Thompson in December 2024, scrutiny on the insurer’s “Deny, Defend, Depose” tactics intensified, yet the operational of denial remained unchanged. For GMR, UHC’s refusal to pay for “medically unnecessary” flights meant that even if a physician on the ground ordered the helicopter, the insurer could void the transaction. This retrospective denial process stripped GMR of the revenue needed to service its $5. 4 billion debt load, forcing the company into a precarious reliance on eventual legal settlements rather than steady cash flow.
The IDR Eligibility Trap
The table details the collapse of the arbitration pathway for air ambulance providers in 2024. While GMR won the vast majority of cases that reached a decision, the volume of cases blocked at the “eligibility” stage rendered those victories pyrrhic.
| Metric | 2023 Rate | 2024 (Q1-Q3) Rate | Impact on GMR |
|---|---|---|---|
| Win Rate (Merits) | 86. 4% | ~85% | High success rate on adjudicated cases. |
| Eligibility Challenges | 37% | 45% | Nearly half of all claims blocked before arbitration begins. |
| Payment Compliance | Delayed | Severe Delays | Insurers like Cigna failed to pay even after losing IDR. |
| Primary Denial Reason | QPA Dispute | Medical need | Shift from price dispute to coverage denial. |
Litigation as a Revenue pattern
With the administrative state failing to enforce payment, GMR turned to the federal courts. In mid-2025, litigation involving Aetna and GMR subsidiaries highlighted the depth of the conflict. Aetna filed counterclaims alleging GMR manipulated the IDR process, while GMR’s subsidiaries argued that insurers were engaged in a coordinated effort to starve air ambulance providers. These lawsuits revealed that insurers were not just denying claims were also ignoring IDR verdicts. In April 2023, GMR had already sued Cigna for failing to pay $2 million in arbitrated awards; by late 2024, the backlog of unpaid “wins” had grown exponentially. The legal costs associated with chasing these payments further eroded GMR’s operating margins.
The liquidity emergency precipitated by these denials forced GMR’s hand. In September 2025, the company executed a $5. 4 billion refinancing deal to restructure its balance sheet. While management framed this as a move to “solidify leadership,” the transaction was a direct response to the cash flow drought caused by payer obstruction. The private equity model requires steady cash to service debt; when insurers like Blue Cross Blue Shield and UnitedHealthcare turned off the tap through medical need denials, GMR had to borrow more money just to stay afloat. The “No Surprises Act” succeeded in protecting patients from balance bills, yet it inadvertently created a regulatory vacuum where insurers could deny payment entirely without immediate consequence.
The Private Equity Exit Strategy: How 2024 Cash Flows Impacted KKR’s Valuation of GMR
The May 2024 “Distressed Exchange”: A Valuation Reset
By the second quarter of 2024, the valuation of Global Medical Response (GMR) had decoupled from its operational reality. While KKR’s internal markers likely held the asset at a premium, the credit markets delivered a harsher verdict. On May 20, 2024, S&P Global Ratings downgraded GMR to ‘SD’ (Selective Default), classifying its debt restructuring as a “distressed exchange.” This event marked the definitive collapse of the 2018 acquisition thesis. The restructuring was not a sign of health a defensive maneuver to avoid a liquidity emergency, extending the maturity of $4. 3 billion in senior secured debt from 2025 to October 2028.
The mechanics of this deal reveal the severity of GMR’s position. To convince lenders to extend the runway, KKR did not refinance; they were forced to inject approximately $962 million in new preferred equity. Crucially, this was structured as Payment-in-Kind (PIK) instruments, meaning GMR would not pay cash interest on this injection. Instead, the interest compounds, adding to the principal balance and further diluting the equity value. This “extend and pretend” strategy allowed KKR to avoid an immediate mark-to-market loss load the company with a capital structure that S&P noted offered lenders “less than originally promised.”
The Cash Flow Mirage: Revenue vs. Collections
The 2024 financial statements presented a paradox that complicated KKR’s exit valuation. On paper, GMR outperformed expectations. While analysts projected an 8% revenue decline, the company reported year-to-date revenue growth of approximately 12. 5% by late 2024. yet, this top-line growth masked a severe deterioration in the quality of cash flows, a direct consequence of the No Surprises Act (NSA).
The Independent Dispute Resolution (IDR) process, intended to settle billing disagreements between insurers and providers, created a massive working capital drag. While GMR “earned” the revenue, it could not collect the cash. The backlog of unpaid claims meant that accounts receivable ballooned, suppressing Free Operating Cash Flow (FOCF). For a private equity sponsor looking to exit, this is toxic; valuations are multiples of EBITDA, debt is serviced by cash. The forced GMR to rely on its revolver and the new PIK equity to maintain liquidity, borrowing money to keep the lights on while waiting for insurers to pay adjudicated claims.
| Metric | Pre-Restructuring (Q1 2024) | Post-Restructuring (Q4 2024) | Impact on Valuation |
|---|---|---|---|
| S&P Credit Rating | CCC+ (Negative) | SD (Default) → B- (Stable) | Confirmed distressed status; increased cost of capital. |
| Debt Maturity | 2025 (Imminent Wall) | October 2028 | Bought 4-year runway locked in higher rates. |
| Equity Injection | N/A | ~$962 Million (PIK Preferred) | Diluted existing equity; interest compounds debt load. |
| Revenue Trend | Forecast -8% Decline | Actual +12. 5% Growth | Positive metric undermined by poor cash conversion. |
| Cash Flow Quality | Standard Collections | High Working Capital Drag | NSA disputes delayed cash, hurting FOCF/Debt ratios. |
The 2026 IPO Attempt: Selling a Debt-Laden Asset
As of February 2026, the consequences of the 2024 restructuring have crystallized into a desperate push for a public exit. Reports indicate KKR has engaged JPMorgan Chase and Bank of America to lead an Initial Public Offering (IPO) aiming to raise $1 billion. This figure is telling. Against a total debt load exceeding $5. 4 billion, a $1 billion equity raise suggests the enterprise value is almost entirely consumed by use. The IPO is not a harvest of profit a liquidity event designed to pay down the expensive debt incurred during the 2024 survival phase.
The valuation KKR seeks in 2026 is predicated on “Adjusted EBITDA”, a metric that adds back the costs of the restructuring, legal fees associated with NSA disputes, and the “phantom” revenue stuck in the IDR process. Institutional investors are being asked to buy the pledge that the cash eventually arrive. If the IPO proceeds, it represents a transfer of the NSA regulatory risk from KKR’s private balance sheet to public market shareholders, locking in the losses of the 2018-2024 period while attempting to salvage the principal investment.
“We view the transaction as distressed because the lenders received less than they were originally promised without sufficient offsetting compensation.”
, S&P Global Ratings, May 20, 2024, regarding GMR’s debt exchange.
Regulatory Failure Points: CMS Audit Results on Non-Compliance with Good Faith Estimates in 2024
The Good Faith Estimate Failure
The IDR “Batching” Scheme
The most significant regulatory failure, yet, occurred within the Independent Dispute Resolution (IDR) process itself. Designed as a last-resort arbitration method, the IDR portal was flooded with disputes, primarily from private equity-backed entities. In mid-2025, a landmark counterclaim by Aetna against GMR subsidiaries—including REACH Air Medical Services, Med-Trans Corporation, and Guardian Flight—exposed the mechanics of this strategy. The insurer alleged that GMR entities were “gaming” the system by artificially unbundling claims. Instead of submitting a single dispute for a transport, providers would separate the “base rate” and “mileage” into distinct IDR claims.
This “batching” strategy had two effects:
1. System Overload: It clogged the CMS portal, contributing to a backlog that exceeded 300, 000 cases by early 2025.
2. Fee Inflation: It forced insurers to pay multiple administrative fees for what was a single medical event, increasing the use of the provider to force a settlement.
| Regulatory method | Provider Failure (GMR/PE-Backed) | Payer Failure (Aetna/Insurers) | widespread Outcome |
|---|---|---|---|
| Good Faith Estimates (GFE) | Failure to provide timely cost estimates for self-pay/uninsured patients; omission of co-provider fees. | N/A | Consumer blindness to true costs; rise in patient complaints to CMS (12, 000+ in 2024). |
| Qualifying Payment Amount (QPA) | Aggressive litigation to vacate QPA methodology; refusal to accept median in-network rates. | CMS Audit Finding: Using “paid amounts” instead of “contracted rates” to artificially lower QPA. | Pricing benchmark is unreliable; arbitration decisions vary wildly ($15k vs $32k). |
| Independent Dispute Resolution (IDR) | “Batching” Strategy: Splitting base rate and mileage into separate disputes to maximize fees. | Delaying payments after IDR rulings; non-compliance with 30-day payment deadlines. | 300, 000+ case backlog; administrative costs consuming healthcare dollars. |
The Aetna Audit:
A Two-Sided Failure The regulatory failure was not unilateral. A major CMS audit of Aetna in July 2024 revealed that insurers were also manipulating the baseline metrics. The audit found Aetna had calculated the Qualifying Payment Amount (QPA), the median in-network rate used as a benchmark in arbitration, incorrectly. By using “paid amounts” rather than “contracted rates,” the insurer artificially depressed the QPA, giving them an unfair advantage in arbitration. This finding handed GMR and other private equity providers a rhetorical weapon. They argued that the “market rates” were rigged by insurers, justifying their aggressive use of the IDR process to secure higher payments. The result was a regulatory death spiral: insurers depressed rates, providers flooded the arbitration system, and the backlog grew so large that the Department of Health and Human Services (HHS) had to repeatedly pause the process to clear the queue.
The Consumer Impact:
For the patient, the “No Surprises Act” succeeded in removing the balance bill failed to control the cost of care. The costs of this regulatory war, legal fees, arbitration costs, and administrative penalties, were absorbed into premium increases. By 2025, the average winning offer in air ambulance arbitration for PE-backed providers had risen to $32, 463, nearly eight times the Medicare reimbursement rate. The regulatory framework of 2024 did not tame the private equity business model; it shifted the extraction point from the patient’s mailbox to the federal arbitration portal.
This air ambulance billing practices report was originally published on our controlling outlet and is part of the media network of 2500+ investigative news outlets owned by Ekalavya Hansaj. The full list of all our brands can be checked here.You may be interested in reading further original investigations here.Â
